Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
120.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
HOPITAL SAINT-LOUIS - LA ROCHELLE
R DU DR SCHWEITZER, 17019 LA ROCHELLE CEDEX 1
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Cell death & disease · 2015
AbstractThe NLR pyrin domain containing 3 (NLRP3) inflammasome is a major component of the innate immune system, but its mechanism of activation by a wide range of molecules remains largely unknown. Widely used nano-sized inorganic metal oxides such as silica dioxide (nano-SiO2) and titanium dioxide (nano-TiO2) activate the NLRP3 inflammasome in macrophages similarly to silica or asbestos micro-sized particles. By investigating towards the molecular mechanisms of inflammasome activation in response to nanoparticles, we show here that active adenosine triphosphate (ATP) release and subsequent ATP, adenosine diphosphate (ADP) and adenosine receptor signalling are required for inflammasome activation. Nano-SiO2 or nano-TiO2 caused a significant increase in P2Y1, P2Y2, A2A and/or A2B receptor expression, whereas the P2X7 receptor was downregulated. Interestingly, IL-1β secretion in response to nanoparticles is increased by enhanced ATP and ADP hydrolysis, whereas it is decreased by adenosine degradation or selective A2A or A2B receptor inhibition. Downstream of these receptors, our results show that nanoparticles activate the NLRP3 inflammasome via activation of PLC-InsP3 and/or inhibition of adenylate cyclase (ADCY)-cAMP pathways. Finally, a high dose of adenosine triggers inflammasome activation and IL-1β secretion through adenosine cellular uptake by nucleotide transporters and by its subsequent transformation in ATP by adenosine kinase. In summary, we show for the first time that extracellular adenosine activates the NLRP3 inflammasome by two ways: by interacting with adenosine receptors at nanomolar/micromolar concentrations and through cellular uptake by equilibrative nucleoside transporters at millimolar concentrations. These findings provide new molecular insights on the mechanisms of NLRP3 inflammasome activation and new therapeutic strategies to control inflammation.
Journal of autoimmunity · 2015
Lupus · 2008
Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant ( P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of graduate medical education · 2025 · Journal Article
Rule ARL, Haq HA, Barnes A, Bowen D, et al.
International journal of medical education · 2024 · Journal Article
Maletsky K, Alali KF, Fanny A, Crouse HL, et al.
Molecular cancer therapeutics · 2024 · Journal Article
Patel E, Malkova NV, Crowe D, Pederzoli-Ribeil M, et al.
Acta clinica Belgica · 2022 · Journal Article
Maloir Q, Laurence S, Christian VF, Fanny G, et al.
The Pan African medical journal · 2020 · Journal Article
Aka EK, Fanny M, Koffi A, Olou NG, et al.
Ophthalmic genetics · 2020 · Case Reports
Balikova I, Sanak NS, Fanny D, Smits G, et al.
Journal francais d'ophtalmologie · 2019 · Journal Article
Ouffoue GY, Boni S, Ouattara AO, Gbe K, et al.
Drug design, development and therapy · 2019 · Journal Article
Kameoka Y, F K, M K
Journal francais d'ophtalmologie · 2016 · Journal Article
Berete CR, Desjardins L, Kouassi LJ, Coulibaly F, et al.
Cell death & disease · 2015 · Journal Article
Baron L, Gombault A, Fanny M, Villeret B, et al.
Gynecologie, obstetrique & fertilite · 2011 · Case Reports
Fanny M, Bringer-Deutsch S, Koffi A, Horo A, et al.
Journal francais d'ophtalmologie · 2008 · Journal Article
Fanny A, Ouattara A, Coulibaly F, Nigué L, et al.
Bulletin de la Societe de pathologie exotique (1990) · 2008 · English Abstract
Ecra AT, Horo A, Fanny M, Ouattara H, et al.
Journal francais d'ophtalmologie · 2007 · Comparative Study
Fanny A, Ouattara A, Aka J, Coulibaly F, et al.
Gynecologie, obstetrique & fertilite · 2006 · Journal Article
Horo GA, Touré-Ecra FA, Fanny M, N'Gbesso D, et al.
Pediatrics · 2024 · Journal Article
Fanny SA, Tam RP, Rule A, Barnes A, et al.
World journal of surgery · 2022 · Journal Article
Ravi K, Killen A, Alexander A, Bell-Davies F, et al.
The western journal of emergency medicine · 2021 · Journal Article
Fanny SA, Kaziny BD, Cruz AT, Camp EA, et al.
Age and ageing · 2025 · Journal Article
Manuel RFJ, Marie-Jeanne K, Fanny B, Stephanie DL, et al.
Psycho-oncology · 2025 · Journal Article
Amandine B, Fanny C, Jessica G, Aurélie B, et al.
BMC genomics · 2012 · Journal Article
Thanh-Son T, Catherine B, Nigel S, Mark F, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2010 · Journal Article
Marino E, Fanny B, Lorenzi C, Pirovano A, et al.
Journal of autoimmunity · 2015 · Journal Article
François A, Gombault A, Villeret B, Alsaleh G, et al.
The Pan African medical journal · 2017 · Case Reports
Aka KE, Apollinaire Horo G, Fomba M, Kouyate S, et al.
Lupus · 2008 · Clinical Trial
F L, Y T, X P, L W, et al.
Age and ageing · 2025 · Journal Article
Manuel RFJ, Marie-Jeanne K, Fanny B, Stephanie DL, et al.
BMJ case reports · 2026 · Journal Article
F A, George OK, Alex AG, Sahitya MS
Frontiers in immunology · 2023 · Journal Article
Nascimento M, Huot-Marchand S, Fanny M, Straube M, et al.
The Pan African medical journal · 2017 · Case Reports
Aka KE, Apollinaire Horo G, Fomba M, Kouyate S, et al.
Pediatrics · 2020 · Journal Article
Foradori DM, Sampayo EM, Fanny SA, Namireddy MK, et al.
BMC pediatrics · 2012 · Clinical Trial
Fanny ML, Beyam N, Gody JC, Zandanga G, et al.